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Supplementary Text

Quantification of genome-wide sites of 5mC, 5hmC, and 5fC/caC at base resolution To gain insight into the global and dynamic changes of genome-wide distribution of 5mC, 5hmC, and 5fC/caC during directed differentiation of iPSCs to neuronal precursor cells (NPC) and neurons (N), we first identified the total number of the modified cytosines in each respective sample. In WT cells, we identified 13637104, 15049856, and 21918240 sites of methylated cytosine (5mC) at iPSC, NPC, and N stages, respectively. By comparative analysis, we observed a 16% and 34% increase of 5mC sites in NPCs and Ns, respectively, compared to iPSCs (Table   S1 ). For 5hmC, we identified 7041346, 7364564, and 10485793 sites in WT iPSCs, NPCs, and Ns, respectively. Changes in 5hmC sites were marked by a 28% decrease in NPCs compared to iPSCs. In contrast, we observed a gain of 5hmC sites as cells differentiate from NPCs to Ns, reaching to similar numbers to that of the iPSC cells (Table S1 ). For 5fC/caC, we identified 2586021, 1797954, and 2307023 sites in WT iPSC, NPC, and N, respectively. The number of 5fC/caC sites was reduced by 10% and 21% in NPCs and neurons, respectively, compared to iPSCs (Table S1 ).
Disease and developmental differences in 5mC, 5hmC, and 5fC/caC landscapes in WT and
PSEN2 cell lines
To characterize changes in the methylome during differentiation along the neural trajectory, we scanned methylomes of the WT and PSEN2 cell lines to comprehensively identify the regions that contain different levels of 5mC (DMR), 5hmC (DHMR), and 5fC/caC (DFCR). In the DMR group we identified a total of 12417 regions, out of which 27.7% belong to the iPSC-specific DMRs with 11.2% being hypermethylated in PSEN2 compared to the WT, while 16.5% was marked by loss of methylation in PSEN2-iPSCs compared to WT-iPSCs. The NPC-specific group was mostly associated with gain of 5mC in PSEN2 (gain DMRs=26.6%) and only a small fraction of 2.9% had loss of 5mC in PSEN2 compared to the WT NPCs. Finally, the neuronspecific DMRs, which consist the largest DMR group (42.9%), showed gain of methylation in 5.6% and loss of methylation in 37.3% of the total DMRs in PSEN2 neurons compared to the WT neurons. In the DHMR group we identified in total 110 regions, where the largest DHMR group was specific to the iPS cells with 12.7% of the regions marked by gain and 25.5% of the regions marked by loss of 5hmC in PSEN2 iPSCs compared to the WT iPSC. The number of NPC-specific DHMRs was marked by identical number of regions (16.4%) that had gains and losses of 5hmC PSEN2 compared to the WT. Lastly, 10% and 19.1% of neuron-specific DHMRs were marked by gain and loss of 5hmC, respectively in PSEN2 cells compared to the WT lines.
In the last group, DFCRs, we identified a total of 694 DFCRs, out of which 12.7% and 14% had gain or loss of 5fC/caC, respectively in PSEN2 iPSC compared to the WT. In the NPC-stage, 10.2% of DFCRs gained 5fC/caC, while 16.3% were marked by loss of 5fC/caC in PSEN2 compared to WT. Finally, in neurons, 27.2% of DFCR gained 5fC/caC, whereas 19.6% of the regions had lost 5fC/caC in PSEN2 compared to the WT (Fig. 4C ).
Functional classification of the genes that were associated with AD-specific signatures
We identified a set of 27 signature regions that were associated with 26 genes. These genes were then grouped into four categories based on their biological functions: 1) neurodevelopment and neuronal transcription factors, 2) critical cellular processes, 3) RNA and associated proteins (including non-coding RNAs), and 4) cell signaling. In the first group, which was also the largest group (10/26), we identified several genes that have been reported to be involved with AD onset or progression, including NR4A2, HTRA1, and INHBB. For example, NR4A2, a transcription factor, which was characterized by loss of 5mC in all AD samples was shown to have a neuroprotective role against inflammation, and its loss of expression was associated with neurodegenerative diseases (36). HTRA1 was marked by loss of 5hmC in all AD samples. This gene specifically degrades APOE4, and inhibition of HTRA1 was associated with increased accumulation of Aβ plaques (37, 38) . In addition, INHBB, a member of TGFβ family, which regulates age-related inflammation processes, was marked by loss of 5fC/caC in AD vs. controls ( Fig. 5A-C, Table S4 ). In the second category (8/26), genes include those involved in DNA repair, inflammation, and mitochondrial functions, all pathways critical in AD pathology. For instance, ECE1 was marked by loss of 5mC in all AD samples. Lack of or lower expression of ECE1 in mice and humans, respectively, was associated with increased amyloid β production (39, 40) . In the third group (5/26), we identified various noncoding RNAs, including long noncoding RNAs and microRNAs. One of the noncoding RNAs, miR-153, which is downregulated in AD and it targets APP (41), was marked by loss of 5mC in all AD samples (Fig. 5A, Table S4 ). In the fourth group (3/26), we identified PTCH1, which encodes for a protein that is involved in the Hedgehog signaling pathway, was marked by loss of 5mC in all AD samples. Overexpression of PTCH1 in Down syndrome was associated with increased levels of APP/AICD (APP intracellular domain) system (42) (Fig. 5A, Table S4 ).
Identification of AD-specific 5mC, 5hmC, and 5fC/caC signature sites To narrow down our regional signatures to individual CpG sites, we first identified the total number of CpG sites that were present in these final signature regions. For the 19 regional signatures in the 5mC groups, in total we identified 355 CpGs, which were then sorted into loss of 5mC CpGs (74) and gain of 5mC CpGs (8) in AD vs. control samples. To avoid background signal and false positives, we applied a final cutoff of methylation fold change difference of ≤-0.1 and ≥0.1, which resulted in 21 loss of 5mC CpGs and 6 gain of methylation CpGs in AD compared to controls (Fig. 5D ). In the final 5hmC regional signatures, we identified 220 total CpG sites, where 14 and 9 CpG sites were marked by loss and gain of 5hmC, respectively, in AD compared to controls. Similar to the 5mC final CpG sites, we applied the final cutoff of methylation fold change difference of ≤-0.1 and ≥0.1, resulting in 3 loss of 5hmC CpGs and 1 gain of 5hmC CpG site in AD vs. normal (Fig. 5D ). Using the same approach as for 5mC and 5hmC, we identified a total of 11 CpG sites in 5fC/caC signature region, with a final 4 gain and 4 loss of 5fC/caC CpG sites in AD compared to controls (Fig. 5D , Table S5 ).
Validation of AD-epigenetic signatures in an independent sample set
To validate our 5mC AD signatures we employed previously published datasets (17). We must note that in the previous study, the authors used bisulfite sequencing that cannot distinguish between 5mC and 5hmC. In addition, the authors used the Illumina 450k array that only covers the coding part of the genome, therefore, it is possible that some of our signature regions might not be present in the ROS/MAP cohort. In our analyses, we employed whole-genome OXBS sequencing that allowed us to identify separately an average of 17,176,031 5mC and 8,479,266 5hmC individual sites. Thus, the Illumina 450k array covers only ~1.6% of our combined 5mC+5hmC sites. Fig. 4 . A-C. Gene ontology functional analysis enrichment was performed using cluterProfiler in Bioconductor. Results were filtered using p<0.05 as inclusion cutoff, and only top 10 terms were kept in each group. Abbreviations: GO: Gene ontology, DMR: differentially methylated regions, DHMR: differentially hydroxymethylated regions, DFCR: differentially formyl/caroboxylated regions.
